Braxia Scientific Corp.
BRAX.CN
Canadian Securities Exchange0.01
CAD
- -
- -
Braxia Scientific Corp.
BRAX.CN
(Canadian Securities Exchange)
Recent
price
0.01
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Braxia Scientific Corp. (CSE:BRAX), founded in 2019 and headquartered in Toronto, Ontario, Canada, operates as a medical research company focused on psychedelic-based therapies for brain-based mental disorders including major depressive disorder, bipolar disorder, suicidality, and related conditions; it previously owned and managed the Braxia Health network of multidisciplinary outpatient clinics offering rapid-acting intravenous ketamine, intranasal esketamine, and psilocybin treatments through its wholly-owned subsidiary Canadian Rapid Treatment Center of Excellence Inc., with locations in Mississauga, Toronto, Ottawa, Montreal, and Kitchener-Waterloo serving patients in Canada and pursuing U.S. segments; the company also advanced research, development, and commercialization of novel ketamine and psilocybin derivatives alongside other psychedelic products and delivery methods via its intellectual property platform, including the KetaMD telemedicine platform. In November 2024, Braxia completed the sale of substantially all assets, particularly those of Canadian Rapid Treatment Center of Excellence Inc., to Kris Kratiuk following shareholder approval, leaving the company with minimal cash, a working capital deficiency exceeding $1.8 million, and only the KetaMD platform intellectual property as its remaining asset; this transaction prompted a failure-to-file cease trade order from the Ontario Securities Commission in August 2024 due to delayed FY2024 financials, trading suspension on the CSE with imminent delisting, executive reductions including director resignations, and plans to wind down operations after settling staff obligations with no intent for further business activities.